PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Active 995, no perso no persop are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

SEP 2'4 2007

(Use as many sheets as necessary)

Co	mplete if Known	1
Application Number	10/583,785	_
Filing Date	06/19/2006	
First Named Inventor	Seeger	
Art Unit		
Examiner Name	tta Chih-Min Kam	
Attorney Docket Number	607927-01	7

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/CMK	/	^{US-} 4,880,776	11-14-1989	Beecham Group P.L.C.	
. / 5. / 1// 11 5.		US-			
	·	US-			
		US-			

	FOREIGN PATENT DOCUMENTS								
Examiner Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages					
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T			
						L			
						L			

Examiner		Date	00/40/0040
Signature	Chih Min Kam/	Considered	08/13/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Traisation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduct

Complete if Known Substitute for form 1449/PTO **Application Number** 10/583,785 INFORMATION DISCLOSURE Filing Date 06/19/2006 STATEMENT BY APPLICANT **First Named Inventor** Seeger Art Unit 1656 ቀቀተተሞ (Use as many sheets as necessary) Chih-Min Kam **Examiner Name** Attorney Docket Number Sheet 2 607927-01

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/CMK./		IDELL S., "Endothelium and disordered fibrin turnover in the injured lung: Newly recognized pathways." Crit. Care Med. (2002) vol. 30, pages 274-280	
000000000000000000000000000000000000000		BERTOZZI, P. et al., "Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome." N. Engl. J. Med., (1990) vol. 30, pages 890-897	
		CAMPELL, E.J. et al., "Extracellular matrix injury during lung inflammation." Chest, (1987) vol. 92, pages 161-167	·
		BURKHARDT, A., "Alveolitis and collapse in the pathogenesis of pulmonary fibrosis." Am. Rev. Respir. Dis. (1989) vol. 140, pages 513-524	
0,0000000000000000000000000000000000000		CREUWELS, L.A.J.M. et al., "The pulmonary surfactant system: Biochemical and clinical aspects." Lung (1997) vol. 175, pages 1-39	
000000000000000000000000000000000000000		HAGGSMANN, H.P. et al., "Surfactant-associated proteins: functions and structural variation." Comp. Biochem. Physiol. A: Mol. Integr. Physiol. (2001) vol. 129, pages 91-108.	
000000000000000000000000000000000000000		CROUCH, E. et al., "Surfactant proteins A and D and pulmonary host defence." Annu. Rev. Physiol. (2001), vol. 63, pages 521-54.	
000000000000000000000000000000000000000		WEAVER, T.E. et al., "Functions of surfactant proteins B and C." Annu. Rev. Physiol. (2001) vol. 63, pages 555-78	
V		SISSON, T.H. et al., "Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes." Human Gene Therapy (1999), vol. 10, pages 2315-2323.	
/CMK./		LEVIN, E.G. et al., "Human hepatoma cell line plasminogen activator." J. Lab. Clin. Med. (1983), vol. 102, pages 500-508.	

Examiner	/Chile Min Mone/	 Date	00/40/0040
Signature	/Chih Min Kam/	 Considered	08/13/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	Substitute for form 1449/PTO			Complete if Known		
Caballia				Application Number	10/583,785	
INF	ORMATION	DIS	CLOSURE	Filing Date	06/19/2006	
STA	TEMENT B	Y A	PPLICANT	First Named Inventor Seeger		
	(Use as many she	ate se r	ocessavi	Art Unit	1656	
	lose as many sne	613 a3 i	·	Examiner Name	tha Chih-Min Kam	
Sheet	3	of	3	Attorney Docket Number	607927-01	

Examiner Cite Initials* No.1		NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
/CMK./		PETER, K. et al., "Construction and in vitro testing of a novel Fab-Hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor Xa-dependent manner." Cardiovasc. Pharmacol., (2003), vol. 42, pages 237-244	at				
300000000000000000000000000000000000000		KERR, D.E. et al., "Comparison of recombinant and synthetically formed monoclonal antibody-bet-lactamase congucates for anticancer" Bioconjugate Chem. (1999), vol. 10, pages 1084-1089.					
		LINDBLADH C. et al., "Use of genetically prepared enzyme conjugates in enzyme immunoassay." Trends Biochem Sci. (1993), vol. 18(8), pages 279-83.					
		SCHERMULY, R.T. et al., "Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (Va/Q) mismatch in a model of acute lung injury." Am. J. Respir. Crit. Care Med. (2000), vol. 161, pages 152-159.					
		CASTELLINO F.J. et al., "Structure and function of the plasminogen/plasmin system." Thromb Haemost (2005), vol. 93, pages 647-54.					
V		DOBROVOLSKY A.B. et al., "The fibrinolysis system: Regulation of activity and physiologic functions of its main components." Biochemistry (Moscow) (2002), vol. 67 (1), pages 99-108					
/CMK./		COLLEN D.C. et al., "Thrombolytic agents." Thromb Haemost (2005), vol. 93, pages 627-30.					
		·					
ļ		·					

Examiner	100 11 8 21 17	Date	00/40/0040
Signature	/Chih Min Kam/	Considered	08/13/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time/you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: